FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295510064> ?p ?o ?g. }

• W4295510064 endingPage "1296" @default.
• W4295510064 startingPage "1287" @default.
• W4295510064 abstract "Background Patients with advanced type B3 thymoma and thymic carcinoma resistant to chemotherapy have few treatment options. We report the efficacy and safety results of the combination of the anti-PD-L1 inhibitor avelumab with the anti-angiogenesis drug axitinib in patients with advanced type B3 thymoma and thymic carcinoma. Methods CAVEATT was a single-arm, multicentre, phase 2 trial, conducted in two Italian centres (the European Instituteof Oncology and the Humanitas Institute, Milan) in patients with histologically confirmed type B3 thymoma or thymic carcinoma, with advanced stage of disease who had progressed after at least one line of platinum-based chemotherapy. Previous treatment with an anti-angiogenesis drug was allowed but not with immune checkpoint inhibitors. Other inclusion criteria were age 18 years or older, an Eastern Cooperative Oncology Group performance status of 0–2, progressive disease, and presence of measurable disease according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1. Patients received avelumab 10 mg/kg intravenously every 2 weeks and axitinib 5 mg orally twice daily until disease progression or unacceptable toxicity. The primary endpoint was the centrally assessed overall response rate according to RECIST version 1.1. Patients who received at least one cycle of treatment and had at least one CT scan after treatment start at scheduled time point by protocol were judged assessable for response and were included in efficacy and safety analyses. This study is registered with EUDRACT, 2017–004048–38; enrolment is completed and follow-up is ongoing. Findings Between April 22, 2019, and June 30, 2021, 32 patients were enrolled. 27 patients had a thymic carcinoma, three a type B3 thymoma, and two a mixed type B3 thymoma and thymic carcinoma. 29 (91%) of 32 patients had stage IVB disease and 13 (41%) of 32 had been pretreated with an anti-angiogenesis drug. 11 of 32 patients had an overall response; thus the overall response rate was 34% (90% CI 21–50); no patients had a complete response, 11 (34%) had a partial response, 18 (56%) had stable disease, and in two patients (6%) progressive disease was the best response. The most common grade 3 or 4 adverse event was hypertension (grade 3 in six [19%] of 32 patients). Four (12%) of 32 patients developed serious adverse events that were new-onset immune-related adverse events, including one grade 3 interstitial pneumonitis, one grade 4 polymyositis, and two grade 3 polymyositis. There were no treatment-related deaths. Interpretation Avelumab combined with axitinib has promising anti-tumour activity and acceptable toxicity in patients with advanced type B3 thymoma and thymic carcinoma progressing after chemotherapy, and could emerge as a new standard treatment option in this setting. Funding Pfizer." @default.
• W4295510064 created "2022-09-14" @default.
• W4295510064 creator A5009015207 @default.
• W4295510064 creator A5009683915 @default.
• W4295510064 creator A5017749409 @default.
• W4295510064 creator A5018378600 @default.
• W4295510064 creator A5022063365 @default.
• W4295510064 creator A5022239860 @default.
• W4295510064 creator A5024763432 @default.
• W4295510064 creator A5040310545 @default.
• W4295510064 creator A5045859251 @default.
• W4295510064 creator A5048497181 @default.
• W4295510064 creator A5052102344 @default.
• W4295510064 creator A5059424755 @default.
• W4295510064 creator A5060492102 @default.
• W4295510064 creator A5074349466 @default.
• W4295510064 creator A5076027732 @default.
• W4295510064 creator A5077342402 @default.
• W4295510064 creator A5080271286 @default.
• W4295510064 creator A5082045927 @default.
• W4295510064 creator A5085211359 @default.
• W4295510064 date "2022-10-01" @default.
• W4295510064 modified "2023-10-18" @default.
• W4295510064 title "Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial" @default.
• W4295510064 cites W1953677527 @default.
• W4295510064 cites W2019607817 @default.
• W4295510064 cites W2083719902 @default.
• W4295510064 cites W2166624818 @default.
• W4295510064 cites W2168071502 @default.
• W4295510064 cites W2168558240 @default.
• W4295510064 cites W2605630275 @default.
• W4295510064 cites W2782183686 @default.
• W4295510064 cites W2784751095 @default.
• W4295510064 cites W2786718111 @default.
• W4295510064 cites W2805302875 @default.
• W4295510064 cites W2808003286 @default.
• W4295510064 cites W2911812451 @default.
• W4295510064 cites W2938876444 @default.
• W4295510064 cites W2972162958 @default.
• W4295510064 cites W2981698704 @default.
• W4295510064 cites W3013672432 @default.
• W4295510064 cites W3034160707 @default.
• W4295510064 cites W3080850044 @default.
• W4295510064 cites W3119086885 @default.
• W4295510064 cites W3174835486 @default.
• W4295510064 cites W3184640918 @default.
• W4295510064 doi "https://doi.org/10.1016/s1470-2045(22)00542-3" @default.
• W4295510064 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36096156" @default.
• W4295510064 hasPublicationYear "2022" @default.
• W4295510064 type Work @default.
• W4295510064 citedByCount "11" @default.
• W4295510064 countsByYear W42955100642022 @default.
• W4295510064 countsByYear W42955100642023 @default.
• W4295510064 crossrefType "journal-article" @default.
• W4295510064 hasAuthorship W4295510064A5009015207 @default.
• W4295510064 hasAuthorship W4295510064A5009683915 @default.
• W4295510064 hasAuthorship W4295510064A5017749409 @default.
• W4295510064 hasAuthorship W4295510064A5018378600 @default.
• W4295510064 hasAuthorship W4295510064A5022063365 @default.
• W4295510064 hasAuthorship W4295510064A5022239860 @default.
• W4295510064 hasAuthorship W4295510064A5024763432 @default.
• W4295510064 hasAuthorship W4295510064A5040310545 @default.
• W4295510064 hasAuthorship W4295510064A5045859251 @default.
• W4295510064 hasAuthorship W4295510064A5048497181 @default.
• W4295510064 hasAuthorship W4295510064A5052102344 @default.
• W4295510064 hasAuthorship W4295510064A5059424755 @default.
• W4295510064 hasAuthorship W4295510064A5060492102 @default.
• W4295510064 hasAuthorship W4295510064A5074349466 @default.
• W4295510064 hasAuthorship W4295510064A5076027732 @default.
• W4295510064 hasAuthorship W4295510064A5077342402 @default.
• W4295510064 hasAuthorship W4295510064A5080271286 @default.
• W4295510064 hasAuthorship W4295510064A5082045927 @default.
• W4295510064 hasAuthorship W4295510064A5085211359 @default.
• W4295510064 hasConcept C121608353 @default.
• W4295510064 hasConcept C126322002 @default.
• W4295510064 hasConcept C141071460 @default.
• W4295510064 hasConcept C143998085 @default.
• W4295510064 hasConcept C203092338 @default.
• W4295510064 hasConcept C2776349617 @default.
• W4295510064 hasConcept C2776539811 @default.
• W4295510064 hasConcept C2776694085 @default.
• W4295510064 hasConcept C2778822529 @default.
• W4295510064 hasConcept C2779159893 @default.
• W4295510064 hasConcept C2779490328 @default.
• W4295510064 hasConcept C2779984678 @default.
• W4295510064 hasConcept C2780352672 @default.
• W4295510064 hasConcept C2911057145 @default.
• W4295510064 hasConcept C3019882237 @default.
• W4295510064 hasConcept C535046627 @default.
• W4295510064 hasConcept C71924100 @default.
• W4295510064 hasConceptScore W4295510064C121608353 @default.
• W4295510064 hasConceptScore W4295510064C126322002 @default.
• W4295510064 hasConceptScore W4295510064C141071460 @default.
• W4295510064 hasConceptScore W4295510064C143998085 @default.
• W4295510064 hasConceptScore W4295510064C203092338 @default.
• W4295510064 hasConceptScore W4295510064C2776349617 @default.
• W4295510064 hasConceptScore W4295510064C2776539811 @default.
• W4295510064 hasConceptScore W4295510064C2776694085 @default.

• next